Race to Contain Iran War Oil Shock as Crude Surges Past 100 Dollars, Markets Slide and Fears Grow Over Prolonged Energy Disruption and Global Inflation Spike G7 finance ministers are preparing an emergency meeting to discuss a possible coordinated release of strategic oil reserves after the Iran war pushed crude above 100 dollars a barrel for the first time since 2022, with Brent briefly nearing 120 dollars. The US‑Israel conflict with Iran has severely disrupted shipments through the Strait of Hormuz, a route that normally carries about a fifth of global oil, driving a sharp spike in crude and gas prices and triggering stock‑market falls. G7 officials fear prolonged fighting could keep energy flows constrained, entrench higher inflation and slow global growth. (Link)
Universal Health Services (NYSE: UHS) to Acquire Talkspace (NASD: TALK) for $5.25/Share in $835 Million All‑Cash Deal to Build National Virtual Behavioral Health Platform Universal Health Services (UHS) has signed a definitive agreement to acquire virtual behavioral health provider Talkspace for $5.25 per share, implying an enterprise value of about $835 million, funded via UHS’s existing revolving credit facility. Talkspace, which generated roughly $229 million in 2025 revenue and delivered more than 1.6 million therapy and psychiatry sessions, brings a network of about 6,000 licensed professionals across all U.S. states, D.C. and Puerto Rico. UHS expects the deal, unanimously approved by both boards and targeted to close in Q3 2026 pending shareholder and regulatory approvals, to be slightly accretive to adjusted EPS in the first year and to accelerate its outpatient and telehealth behavioral health strategy. (Link)
Agilent Technologies (NYSE: A) to Acquire Biocare Medical for $950 Million Cash, Expanding High-Growth Pathology Antibody Platform and Targeting EPS Accretion Within 12 Months Agilent Technologies (NYSE: A) has signed a definitive agreement to acquire Biocare Medical, a high-growth clinical pathology specialist, in an all-cash deal valued at $950 million. Biocare, a leader in IHC, ISH and FISH solutions with more than 300 antibodies and over $90 million of 2025 revenue, has delivered double-digit revenue and profit growth since 2021. The transaction will expand Agilent’s pathology portfolio, strengthen its U.S. footprint and accelerate antibody menu development. Management expects the deal to be accretive to growth, margins and non-instrument mix in year one and to EPS about 12 months post-close. (Link)
Saisystems Health and Serent Capital Partner to Scale AI-Enabled RCM and EHR Solutions Saisystems Health, a provider of technology-enabled revenue cycle management (RCM) and electronic health records (EHR) for post-acute care, has announced a strategic partnership with private equity firm Serent Capital. While the specific financial terms were not disclosed, the investment is aimed at accelerating Saisystems’ product innovation, specifically enhancing its AI capabilities to streamline clinical workflows and financial performance for skilled nursing facilities and physician groups. The partnership leverages Serent’s expertise in scaling healthcare technology companies to expand Saisystems’ market footprint. (Link)
Integration Health Expands Portfolio with Acquisition of Perfusion Life via its financial sponsor 1315 Capital Integration Health has successfully completed the acquisition of Perfusion Life, a leading provider of perfusion staffing and management services. This strategic move is designed to bolster Integration Health’s clinical service offerings across hospitals and surgical centers. By integrating Perfusion Life’s specialized expertise, Integration Health aims to optimize cardiovascular surgical support and staffing efficiency. The acquisition reflects a broader strategy of consolidating niche clinical services to provide a more comprehensive, integrated care delivery model for healthcare systems nationwide. (Link)
Surgery Partners Acquires Preferred Vascular Group to Expand Multispecialty Surgical Platform its financial sponsor Bain Capital Surgery Partners, Inc. has acquired Preferred Vascular Group (PVG), a provider of vascular care services. This acquisition integrates PVG’s high-quality vascular access centers into Surgery Partners’ extensive national network of ambulatory surgical centers. The deal is intended to enhance Surgery Partners’ specialty care capabilities, particularly in the outpatient vascular space, providing patients with more accessible and cost-effective treatment options. This move follows trends of shifting high-acuity procedures to lower cost, outpatient environments. (Link)
Gedeon Richter Expands Women’s Health Portfolio through Acquisition of Celmatix’s Drug Discovery Assets Global pharmaceutical company Gedeon Richter has acquired the women’s health drug discovery portfolio from Celmatix Inc. The deal includes several preclinical programs focused on first-in-class treatments for conditions such as PCOS and endometriosis. This acquisition strengthens Gedeon Richter’s position as a leader in women’s healthcare by integrating Celmatix’s AI-driven “Transcriptomic Cohort” data to identify novel therapeutic targets. The partnership emphasizes a shared commitment to addressing underserved medical needs in reproductive health through cutting-edge genomic research and clinical development. (Link)
Quantum Health Bolsters Virtual Care Strategy with Acquisition of CirrusMD via its financial sponsors Great Hill Partners and Warburg Pincus. Quantum Health, a leading consumer healthcare navigation company, has acquired CirrusMD, a provider of physician-led integrated virtual care. This acquisition enables Quantum Health to integrate CirrusMD’s “text-first” virtual care platform into its navigation services, offering members immediate access to physicians. The synergy aims to reduce healthcare costs and improve outcomes by closing gaps in care through early intervention. The deal reflects Quantum Health’s strategy to provide a seamless, end-to-end healthcare experience that combines human navigation with advanced digital health tools. (Link)
TPG Capital Partners with Findhelp to Enhance Social Care Access for Underserved Populations Global alternative asset firm TPG, through its Rise Fund, has partnered with Findhelp, the leading social care network in the United States. The investment is geared toward scaling Findhelp’s platform, which connects individuals in need with local social service organizations. TPG’s involvement will support Findhelp in expanding its reach among healthcare providers, insurers, and government agencies. By addressing social determinants of health (SDOH), the partnership aims to improve health outcomes and equity for millions of Americans by streamlining the referral process for food, housing, and financial assistance. (Link)
American Reproductive Centers Acquires Mississippi Fertility Institute for $4.25 Million Alabama-based American Reproductive Centers (ARC) has expanded its regional presence by acquiring the Mississippi Fertility Institute in a deal valued at $4.25 million. This acquisition is part of ARC’s strategic effort to increase access to advanced reproductive technologies and fertility treatments across the Southeast. By integrating the Jackson-based clinic into its network, ARC plans to upgrade facilities and introduce new clinical protocols to improve patient success rates. The deal underscores a growing trend of regional consolidation within the highly specialized fertility and IVF market. (Link)
DoseSpot and Arrive Health Merge to Improve Prescription Access and Price Transparency via its financial sponsors Bain Capital Tech Opportunities, PSG and UPMC Enterprises DoseSpot, a leading e-prescribing platform, and Arrive Health, a provider of real-time prescription benefit tools, have announced a merger. This combination aims to create a unified platform that integrates clinical workflows with financial transparency, allowing clinicians to see accurate drug pricing at the point of care. The merger is designed to improve medication adherence and reduce administrative burdens for providers. By joining forces, the entities seek to solve the critical challenge of drug affordability, ensuring patients can access the most cost-effective medications prescribed by their doctors. (Link)
Adobe Population Health Acquires Eventa LLC to Integrate Respiratory Care Solutions Adobe Population Health has expanded its clinical service suite through the acquisition of Eventa LLC, a specialist in respiratory care management. This acquisition allows Adobe to offer specialized services for patients with chronic respiratory conditions, such as COPD and asthma, within its population health management framework. By incorporating Eventa’s expertise, Adobe aims to reduce hospital readmissions and improve the quality of life for high-risk patient populations. The move highlights Adobe’s commitment to building a comprehensive, multi-disciplinary approach to managing complex chronic diseases. (Link)
Freeman Health System to Acquire Four Arkansas Hospitals from Community Health Systems (CHS) Community Health Systems (CHS) has signed a definitive agreement to sell four of its Arkansas-based hospitals to Freeman Health System. The transaction includes facilities in El Dorado, Springdale, and Bentonville. This divestiture is part of CHS’s ongoing portfolio optimization strategy to focus on core markets. For Freeman Health System, the acquisition represents a significant geographic expansion, allowing the non-profit system to provide a broader continuum of care to residents in the Arkansas region while investing in facility upgrades and clinical services. (Link)
MUSC Health Expands Statewide with $111 Million Acquisition of Palmetto Primary Care MUSC Health has announced a $111 million deal to acquire Palmetto Primary Care Physicians, one of the largest independent multi-specialty groups in South Carolina. This strategic acquisition significantly broadens MUSC’s primary care footprint, adding over 100 providers across 30 locations. The investment is focused on creating a more seamless “hub-and-spoke” model of care, ensuring patients have easier access to MUSC’s specialized academic medical services through their local primary care offices. The deal reflects MUSC’s mission to provide comprehensive, integrated healthcare coverage throughout the state. (Link)
Seal Shield Acquires Vioguard to Expand UV-C Sanitization Solutions in Healthcare Seal Shield, a leader in medical-grade infection control hardware, has acquired Vioguard, a pioneer in UV-C LED disinfection technology. This acquisition enhances Seal Shield’s portfolio of sanitization solutions designed to eliminate pathogens on high-touch surfaces in clinical environments. By integrating Vioguard’s patented UV-C technology, Seal Shield aims to offer more robust, automated disinfection tools to hospitals and clinics, helping to reduce healthcare-associated infections (HAIs). The deal positions Seal Shield as a comprehensive provider of both antimicrobial hardware and advanced disinfection systems. (Link)
National Healthcare Properties and Discovery Senior Living Complete $64 Million Acquisition National Healthcare Properties, in partnership with Discovery Senior Living, has closed a $64 million acquisition of a senior housing portfolio. This investment is part of a broader strategy to modernize and expand senior living communities to meet the rising demand for high-quality assisted living and memory care services. Discovery Senior Living will manage the properties, implementing its “experiential” living model. The deal highlights the continued interest of institutional real estate investors in the senior housing sector, driven by favorable demographic trends and the need for specialized care facilities. (Link)
Patient Advocate Foundation and PAN Foundation Announce Landmark MergerThe Patient Advocate Foundation (PAF) and the Patient Access Network (PAN) Foundation have announced their intention to merge, creating a powerhouse in the patient assistance sector. This merger will combine PAF’s case management and navigation services with PAN’s financial assistance programs for underinsured patients. By joining forces, the organizations aim to provide a more holistic support system for individuals facing life-threatening and chronic illnesses. The unified entity will focus on reducing financial barriers to care and improving health equity through expanded advocacy and direct patient support services. (Link)
Venture and Other News:
Minnesota Medical Technologies Secures $20 Million Series A Led by Versant Ventures Minnesota Medical Technologies (MMT) has closed a $20 million Series A funding round led by Versant Ventures, with participation from existing investors. MMT is a medical device firm focused on developing innovative solutions for urological and GI health. The capital will be used to accelerate the development and clinical validation of its flagship fecal incontinence treatment device. MMT aims to address a significant unmet need in the market with its minimally invasive technology, and the new funding will support toward FDA clearance and commercial launch in the U.S. market. (Link)
llumia Ventures Leads $20.5M Series B in Greater Good Health; DaVita Venture Group and Blue Cross of Idaho’s Granite Financial Join, with $12.5M Debt Facility from HSBC Innovation Banking Greater Good Health, a value-based primary care provider centered on nurse practitioners, raised $20.5 million in Series B funding led by Allumia Ventures, with participation from DaVita Venture Group, Granite Financial Holdings (Blue Cross of Idaho’s investment arm), and existing investors including Optum Ventures and Flare Capital Partners. The company also secured up to $12.5 million in venture debt from HSBC Innovation Banking. Serving over 200,000 patients, Greater Good Health will use the funds to expand its value-based care model, deepen payer partnerships, and extend its geographic footprint, addressing primary care shortages and rising healthcare costs. (Link)
NexCure Raises $19 Million Series A to Advance Immuno-Oncology Pipeline NexCure, a clinical-stage biopharmaceutical company, has successfully raised $19 million in a Series A funding round. While specific lead investors were not named in initial reports, the round included participation from several prominent life science venture firms. The funding will be directed toward advancing NexCure’s lead candidate through Phase 1 clinical trials and supporting the discovery of new drug targets for cancer immunotherapy. NexCure utilizes a proprietary functional screening platform to identify novel proteins that modulate the immune system, aiming to develop therapies for patients who do not respond to existing treatments. (Link)
Sage Secures $65 Million Series C Led by Goldman Sachs including ANEW Capital and Maveron to Scale AI Senior Care Platform Sage, a technology platform designed to modernize eldercare, has raised $65 million in a Series C funding round led by Goldman Sachs Asset Management. The round also saw participation from ANEW Capital and Maveron. Sage’s platform uses AI to help senior living staff monitor residents more effectively, prioritizing care based on real-time data to prevent emergencies. This new capital will be used to scale Sage’s operations, enhance its AI algorithms, and expand its reach into more senior living communities across the United States, addressing the critical staffing shortages in the industry. (Link)
Science Corporation Closes $230 Million Series C to Commercialize BCI Retinal Implant backed by Founders Fund, Lux Capital, and Paradigm Science Corporation, a leader in brain-computer interface (BCI) technology, has raised $230 million in a Series C round. The funding was backed by a diverse group of investors, including Founders Fund, Lux Capital, and Paradigm. The capital is earmarked for the commercialization of its PRIMA retinal implant, a sub-retinal device designed to restore vision in patients with geographic atrophy due to age-related macular degeneration. Following successful clinical results, Science Corp aims to use this massive infusion of capital to build out its manufacturing capabilities and prepare for a global product launch. (Link)
UnityAI Raises $8.5 Million Seed Round to Deploy AI Agents for Healthcare Workforce led by Max Ventures and General Catalyst UnityAI has secured $8.5 million in seed funding led by Max Ventures and General Catalyst. The startup is developing AI-driven “agents” designed to automate administrative tasks and optimize patient flow within hospital settings. The goal of the technology is to alleviate the burnout experienced by healthcare workers by handling scheduling, bed management, and documentation. This initial capital will allow UnityAI to expand its engineering team and launch pilot programs with several large health systems, proving the efficacy of AI in managing complex hospital operations and improving staff retention. (Link)
Grow Therapy Hits $3 Billion Valuation Following New Funding Round Led by TCV with participation from Transformation Capital and SignalFire Mental health platform Grow Therapy has reached a “unicorn” valuation of $3 billion after a new funding round led by TCV, with participation from Transformation Capital and SignalFire. Grow Therapy provides an integrated platform that helps independent therapists manage their practices while connecting patients with affordable, insurance-covered mental health care. The fresh capital will be used to further develop its AI-driven matching tools and expand its network of providers. The high valuation underscores the surging investor interest in mental health startups that solve the accessibility and affordability crisis. (Link)
KeyCare Raises $27.4 Million to Scale AI-Powered Epic-Based Virtual Care featuring 8VC, LRVHealth, and Health Catalyst Capital KeyCare, the nation’s first Epic-based virtual care company, has raised $27.4 million in a funding round featuring 8VC, LRVHealth, and Health Catalyst Capital. KeyCare allows health systems to expand their virtual care capacity by providing access to a network of independent “virtualist” providers who share the same EHR platform. This funding will support the expansion of KeyCare’s AI capabilities, which help triaging patients and streamlining the virtual visit process. By staying within the Epic ecosystem, KeyCare ensures seamless data sharing and continuity of care between virtual visits and in-person health system services. (Link)
Polares Medical Raises $50 Million Series C for U.S. Expansion of Mitral Valve Technology led by Decheng Capital and Endeavour Vision Polares Medical, a clinical-stage medical device company, has closed a $50 million Series C round led by Decheng Capital and Endeavour Vision. The company is developing the MRace Mitral Reshaping System, a hemi-replacement technology for treating mitral regurgitation. The funding will support the company’s expansion of clinical trials in the United States and the pursuit of regulatory approvals. Polares aims to provide a more physiological solution for heart valve repair, and this investment signifies strong investor confidence in the company’s unique approach to structural heart disease. (Link)
Teen-Built AI Calorie App “Cal AI” Generates $40 Million and Gains Interest from MyFitnessPal Cal AI, an AI-powered calorie-tracking app built by a 19-year-old entrepreneur during high school, has reportedly generated $40 million in revenue and attracted significant investment interest, including talks with MyFitnessPal and various Silicon Valley VCs. The app uses advanced computer vision to estimate caloric intake from photos of food with high accuracy. The success of the app highlights the power of “solopreneur” developers in the AI space. While a formal venture round hasn’t been closed, the founder is currently evaluating offers to scale into a broader metabolic health platform. (Link)
Ease Health Emerges from Stealth with $41 Million Led by Andreessen Horowitz (a16z) with support from Benchmark and F-Prime Capital. Ease Health has launched with $41 million in funding led by Andreessen Horowitz (a16z), with support from Benchmark and F-Prime Capital. The company is building what it describes as the “operating system for behavioral health,” a comprehensive software suite that integrates clinical notes, billing, and patient engagement for mental health clinics. By automating the “back-office” burden, Ease Health aims to allow therapists to focus more on patient care. The investment will be used to scale the platform nationally and integrate AI tools that help clinicians track patient progress over time. (Link)
Procode AI Raises $4 Million in Seed Funding to Automate Medical Coding round led by Eniac Ventures and Afore Capital Procode AI, a startup utilizing generative AI to automate medical coding and billing, has raised $4 million in a seed round led by Eniac Ventures and Afore Capital. The company’s platform analyzes clinical documentation in real-time to assign accurate medical codes, reducing errors and speeding up the reimbursement process for providers. This funding will be used to enhance the platform’s accuracy across different medical specialties and to expand the sales team. Procode AI enters a competitive market but aims to differentiate itself through its deep integration with existing EHR systems. (Link)
Ro: Serena Williams promotes GLP-1 telehealth. (Link)
Novartis: Encourages prostate cancer blood test screening. (Link)
Boehringer Ingelheim: Raises awareness for kidney disease screening. (Link)
TrumpRx launches with AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer to offer discounted drugs for U.S. cash‑paying patients under Most favoured Nation policy The TrumpRx direct‑to‑consumer platform introduces over 40 discounted prescription drugs to help uninsured or cash‑paying U.S. patients access more affordable treatments. The initiative, backed by the first five pharmaceutical companies signing pricing deals under the Most Favoured Nation policy, includes major blockbusters such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both offered at significantly reduced prices. Additional products include insulin, fertility therapies, and inhalers from Pfizer and others. Sixteen global drugmakers are expected to join the platform, which aims to align U.S. medication prices with international standards while reshaping the domestic pricing landscape and consumer access dynamics. (Link)
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal Takeda Pharmaceutical enters multi-year AI drug discovery collaboration with Iambic Therapeutics worth more than $1.7 billion to accelerate small-molecule development in oncology, inflammation, and gastrointestinal diseases. The partnership underscores Takeda’s push to fully integrate AI into its R&D engine, following prior deals like its Nabla Bio collaboration, as big pharma bets on AI to speed discovery, reduce costs, and target complex diseases more precisely. Iambic, a San Diego-based biotech with a growing pipeline of AI-discovered candidates, gains validation and funding to expand its platform amid surging interest in AI-driven drug design. (Link)
Once Upon a Farm (NYSE: OFRM) raises $198M in NYSE IPO backed by Goldman Sachs and J.P. Morgan to expand organic children’s food business co-founded by Jennifer Garner The company’s public debut marks a major milestone for the organic children’s food brand, offering 11 million shares at $18 each. Founded by Cassandra Curtis and Ari Raz in 2015 and later joined by Jennifer Garner and John Foraker, Once Upon a Farm produces cold-pressed pouches, frozen meals, and oat bars made from responsibly sourced fruits and vegetables. The IPO strengthens its ability to meet rising consumer demand for clean, nutritious food products while amplifying its retail presence. Despite global supply challenges, the company aims to grow amid increasing momentum in the health-conscious food and beverage market. (Link)
TenetHealthcare (NYSE: THC) receives $1.9B from CommonSpirit to regain full ownership of Conifer Health Solutions Under the agreement, CommonSpirit will pay Tenet Healthcare $1.9 billion in instalments over three years to sell its 23.8% equity stake in Conifer Health Solutions, Tenet’s revenue cycle management subsidiary. The transaction, retroactive to January 1, 2026, also includes a $540 million payment from Conifer to eliminate CommonSpirit’s capital account and finalize the stake redemption. Conifer will continue providing services to CommonSpirit through the end of 2026 while onboarding new clients. Tenet expects the move to strengthen its financial outlook, citing operational efficiency, revenue growth, and strategic alignment as key drivers for sustaining profitability and future expansion. (Link)
PrimeGen US to merge with DT Cloud Star Acquisition Corporation (NASD: DTSQ) in a $1.5B business combination to accelerate stem cell and exosome therapy development The merger will position PrimeGen US for public market access and expanded funding to advance its regenerative medicine portfolio. The company’s lead program centers on its proprietary Triple Activated Mesenchymal Stem Cell (MSC) platform, being developed as a treatment for acute alcoholic hepatitis and other liver-related conditions. The deal, expected to close in the second half of 2026 pending shareholder and regulatory approvals, will support clinical progression, regulatory submissions, and potential commercialization. PrimeGen’s leadership emphasized that the transaction marks a major step toward scaling its two-decade foundation in stem cell innovation into transformative therapies for critical diseases. (Link)
Eikon Therapeutics (NASD: EIKN) raises $381M in upsized Nasdaq IPO, the largest biotech listing since 2024, led by former Merck executive Roger Perlmutter Proceeds from the public offering will fund the clinical advancement of Eikon’s oncology pipeline, notably EIK1001, a toll-like receptor 7/8 agonist currently studied with Keytruda in melanoma and lung cancer. Additional programs include PARP1 inhibitors EIK1003 and EIK1004—targeting ovarian, breast, prostate, and pancreatic cancers—and EIK1005, a WRN helicase inhibitor in early-stage development for solid tumours. The company, founded in 2021, continues to build momentum on its immunotherapy and precision oncology strategy, backed by prior multimillion-dollar financing rounds that have supported rapid progression from preclinical research to multiple active phase 1/2 and 2/3 trials across critical cancer indications. (Link)
SpyGlass Pharma (NASD: SGP) launches $150M Nasdaq IPO for advancing long-acting eye drug delivery innovation Funds from the IPO will advance SpyGlass Pharma’s lead candidate, the Bimatoprost Drug Pad-IOL System, a long-acting intraocular lens designed to deliver sustained treatment for glaucoma and ocular hypertension. The device, implanted during cataract surgery, provides years of drug release, potentially eliminating the need for daily eye drops. Proceeds will support two phase 3 clinical trials already underway and a potential commercial rollout upon successful results. Early studies demonstrated significant intraocular pressure reduction, affirming the platform’s promise. SpyGlass joins a wave of biotech companies reinvigorating the IPO market as investors renew interest in ophthalmic and drug-delivery innovations. (Link)
Agomab Therapeutics (NASD: AGMB) raises $200M in Nasdaq IPO to support development of ALK5 inhibitors for fibrostenosing Crohn’s disease and pulmonary fibrosis Proceeds from the IPO will fund Agomab Therapeutics’ next-stage clinical programs, including a global phase 2b trial for ontunisertib, its leading oral ALK5 inhibitor targeting fibro stenosing Crohn’s disease. The company also plans to advance AGMB‑447, another ALK5 inhibitor in phase 1 studies for idiopathic pulmonary fibrosis, toward midstage development. Both candidates were obtained through Agomab’s 2021 acquisition of Origo Biopharma. The IPO proceeds will also bolster operational growth and global research capabilities as Agomab pursues fibrosis-modifying therapies aimed at halting disease progression in patients with chronic intestinal and respiratory conditions. (Link)
Veradermics (NYSE: MANE) raises $256M in NYSE IPO with investment interest from Eli Lilly and Wellington Management to advance oral minoxidil hair regrowth therapy The Connecticut-based biotech’s IPO marks a strong debut, with shares more than doubling in their first trading session. Veradermics focuses on developing VDPHL01, an extended-release oral version of minoxidil, intended to overcome limitations of topical Rogaine. The funds will support phase 3 trials evaluating its efficacy in treating pattern hair loss. Eli Lilly expressed interest in acquiring up to 4.9% of issued shares, while Wellington Management indicated plans to invest up to $30 million. The company seeks to capture a major share of the expanding global hair loss market and lead innovation in convenient, effective hair restoration therapies. (Link)
Kaiser Permanente and Renown Health complete joint venture to jointly own Hometown Health and expand integrated care access in northern Nevada The finalized partnership marks Kaiser Permanente’s entry into northern Nevada through the joint ownership of Hometown Health and collaboration with Renown Health’s established provider network. The venture aims to expand access to affordable, value-based care while integrating insurance coverage and clinical delivery across the region. Kaiser Permanente will open two new medical centers in 2026, adding to its existing Reno location, and plans to introduce its digital health platform and in-house pharmacy network by 2027. The collaboration combines Kaiser Permanente’s national capabilities with Renown’s strong local presence to enhance clinical outcomes and improve patient experience across northern Nevada. (Link)
NuvemRx acquires 340B referral technology company par8o from R1 RCM, via its financial sponsors Parthenon Capital Partners and Rainmaker Strategic Capital to enhance specialty care coordination and expand pharmacy network capabilities The acquisition integrates par8o’s AI-powered referral capture technology with NuvemRx’s pharmacy management and third-party administration services, enabling covered entities to more efficiently manage 340B referrals and specialty prescriptions. The combined platform now supports over 800 covered entities and impacts more than 70 million patients nationwide. By automating up to 85% of the referral and eligibility process, the integration reduces administrative burdens, enhances compliance, and increases savings opportunities for safety-net providers. The move strengthens NuvemRx’s mission to simplify pharmacy operations, expand access to affordable care, and improve coordination across community health and specialty care networks. (Link)
MedRisk to acquire Horizon Casualty Services PPO Network business from Horizon Mutual Holdings, via its financial sponsors CVC Capital Partners and The Carlyle Group to expand managed care capabilities in workers’ compensation and auto casualty markets The acquisition enhances MedRisk’s reach and service offerings within the casualty claims industry by integrating Horizon Casualty Services’ PPO Network business. The move aligns with MedRisk’s strategy to deliver improved patient outcomes, streamlined claims management, and optimized payment solutions. The integration supports faster recovery times, smarter spending, and enhanced client value while reinforcing the company’s commitment to innovation and superior service across workers’ compensation and auto casualty markets. (Link)
Coloplast discloses definitive agreement for Uramedica acquisition in Q1 2025/26 earnings Report Coloplast US signs definitive merger agreement to acquire all outstanding shares of Uromedica, a privately held US medtech company specializing in minimally invasive treatments for stress urinary incontinence, making Uromedica a wholly owned subsidiary. The acquisition is expected to close in February 2026, subject to customary closing conditions and requisite Uromedica shareholder approval. The move aligns with Coloplast’s strategy to bolster growth in urology through targeted additions, amid strong organic performance in the division. (Link)
Konovo acquires Rare Patient Voice, via its financial sponsors Bain Capital Credit, Frazier Healthcare Partners, GV Investment Managers and Leavitt Equity Partners to expand access to 200,000+ patients and caregivers The acquisition strengthens Konovo’s healthcare intelligence platform by combining its data-driven capabilities and healthcare provider network with Rare Patient Voice’s extensive, community-driven database of patients and caregivers. This integration enhances the ability of researchers to access hard-to-reach populations and capture real-world patient insights across therapeutic areas. Konovo plans to scale these efforts globally while integrating patient and clinician perspectives into unified, technology-enabled research solutions. The partnership drives faster, more informed decision-making for healthcare organizations advancing innovation in complex diseases. (Link)
RadNet (NASD: RDNT) acquires Northwest Radiology in Indiana, adding six imaging centers to expand Midwest footprint and enhance AI-powered diagnostic services The acquisition marks RadNet’s entry into Indiana, extending its national imaging network into the Midwest through six outpatient centers in the Indianapolis region. Northwest Radiology’s 18 radiologists will continue providing contracted professional services, ensuring continuity and maintaining strong local physician relationships. The integration will leverage RadNet’s advanced imaging technologies and AI-driven workflows to improve early disease detection and overall population health management. With the addition expected to generate approximately $18 million in annual revenue, RadNet aims to expand its proactive diagnostic approach while strengthening patient access to high-quality, cost-effective imaging care across Indiana. (Link)
Nautic Partners completes growth investment in KabaFusion as Novo Holdings exits, supporting expansion of home infusion care services The partnership marks a new phase for KabaFusion, a national leader in home and alternate site infusion therapy. With operations covering 45 states through 33 pharmacies and 21 infusion suites, the company will leverage Nautic Partners’ investment to accelerate its growth and innovation initiatives. KabaFusion’s management team, which remains significant investors, will continue leading the organization to enhance patient access and clinical excellence. The investment underscores Nautic’s strategy of backing mission-driven healthcare providers delivering high-quality, patient-centered care, marking the exit of Novo Holdings following its successful tenure supporting KabaFusion’s nationwide expansion. (Link)
Black Pearl Equities Announces Intention to Commence Tender Offer to Acquire Selectis Health, Inc. Black Pearl Equities, LLC announces intention to commence an all-cash tender offer to acquire all issued and outstanding shares of common stock of Selectis Health, Inc. (OTC: GBCS) at $4.00 per share. The proposed transaction is subject to negotiation and execution of definitive transaction documentation as well as customary closing conditions. Selectis Health operates skilled nursing and transitional care facilities, and this unsolicited proposal follows the company’s recent asset sales and operational streamlining efforts. (Link)
Vanderbilt Health acquires Tennova’s Clarksville Hospital, Tennova ER-Sango, and physician clinics from Community Health Systems to expand regional care network The acquisition expands Vanderbilt Health’s footprint across Middle Tennessee, adding the 270-bed Clarksville hospital, freestanding Sango ER, and multiple physician practices to its growing regional system. Vanderbilt Clarksville Hospital (VCH) will serve as a hub for expanded emergency, surgical, and specialty services, with new paediatric and adult programs planned in collaboration with Monroe Carell Jr. Children’s Hospital. The integration brings nearly 1,100 staff and over 30 physicians into Vanderbilt’s network, reinforcing its commitment to delivering high-quality, community-based care. The move marks Vanderbilt’s fourth regional hospital acquisition, extending its reach beyond Nashville and strengthening access to advanced health services statewide. (Link)
Venture and Other News
Midi Health closes $100M Series D in Goodwater Capital–led round with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens and McKesson Ventures to scale national women’s health platform The virtual women’s health clinic now serves over 230,000 patients across 50 states through a network of 500 providers, treating 25,000 patients weekly. Founded in 2021 to address perimenopause and menopause care, the company is expanding into metabolic health, weight management, and musculoskeletal health. The platform uses AI-powered tools for chart analysis, scheduling, and care protocols while offering insurance-backed services reaching 45 million women. The company reports improved screening adherence rates and up to 13% lower total cost of care, with plans to expand Medicare and Medicaid coverage. (Link)
Chamber raises $60M Series A led by Frist Cressey Ventures with General Catalyst, AlleyCorp, American Family Ventures, Company Ventures, Optum Ventures, Healthworx Ventures and Black Opal Ventures to scale cardiology value-based care The funding will accelerate Chamber’s mission to modernize cardiovascular care through value-based models that improve outcomes while lowering costs. The company’s platform integrates AI-driven insights to help cardiologists identify high-risk patients, close care gaps, and streamline workflows within existing systems. Partnering with both payers and practices, Chamber supports data-informed, proactive management of chronic heart disease. With more than 500 cardiologists across seven states already on its network, the company plans to expand its national footprint and strengthen partnerships with health plans. The investment underscores growing momentum behind value-based innovations addressing cardiovascular care delivery and patient experience. (Link)
Alaffia Health raises $55M Series B led by Transformation Capital with FirstMark Capital, Tau Ventures, and Twine Ventures to expand AI-driven health plan operations The latest funding round accelerates Alaffia Health’s mission to reduce healthcare’s $570 billion in administrative waste through advanced, clinically informed AI for health plan claims management. The company’s platform combines physician oversight with agentic AI to enhance accuracy, speed reviews, and achieve measurable cost savings for national and regional payers. Delivering over 20% savings on high-cost claims and fivefold ROI, Alaffia plans to use the new capital for R&D, product innovation, and scaling adoption across the healthcare ecosystem. The investment supports ongoing efforts to create transparent, compliant, and efficient claims infrastructure that strengthens affordability and systemwide operational performance. (Link)
Third Arc Bio raises $52M Series A extension led by Andreessen Horowitz with Omega Funds, Goldman Sachs Alternatives, BVF Partners, T. Rowe Price, Galapagos NV, AbbVie Ventures and Alderline Group to advance oncology and immunology pipeline The funding strengthens Third Arc Bio’s efforts to expand its multifunctional antibody programs in oncology and immunology. The capital will accelerate clinical development of the company’s lead asset, ARC101—a bispecific T cell engager targeting CLDN6 in advanced solid tumours—while advancing next-generation inflammation and immune modulation candidates toward human trials. Leveraging its ARCTag (Tethered Agonist) platform, Third Arc Bio aims to localize immune activity precisely at disease sites, enhancing efficacy and reducing systemic toxicity. Supported by a seasoned scientific team, the company continues to validate its platform approach to develop targeted biologics addressing major unmet medical needs. (Link)
Market Rumours
Seed Health reportedly retains Centerview Partners to explore potential sale amid strong financial performance Seed Health has reportedly hired Centerview Partners to advise on a potential sale as it attracts strong interest from strategic and private equity buyers. Generating about $200 million in revenue and over $50 million in EBITDA, the company aims to leverage rising global demand for premium probiotics and wellness products.
HHAeXchange reportedly explores sale with Centerview Partners advising; backed by Cressey & Company and Hg Capital The company, generating about $100 million in recurring revenue, develops software that streamlines compliance and operations for Medicaid homecare providers. Having expanded through acquisitions of Sandata Technologies, Generations Homecare Systems, and Cashe Software, it reflects growing investor interest in post‑acute healthcare tech consolidation during ongoing strategic review discussions.
